24/7 Market News Snapshot 24 October, 2025 – Neuraxis, Inc. (NYSE:NRXS)

October 24, 2025

DENVER, Colo., 24 October, 2025 (www.247marketnews.com) – (NYSE:NRXS) are discussed in this article.
Neuraxis, Inc. (NRXS) is seeing an impressive surge in pre-market trading, with shares reaching $4.718—an increase of 23.51% from the previous day’s close of $3.820. This remarkable performance is accompanied by significant trading volume of 7.26 million shares, reflecting a robust investor enthusiasm. The bullish trend in NRXS stock signals heightened market confidence, driven by recent developments that could offer promising catalysts for growth.

In a pivotal advancement, Neuraxis has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (PENFS) technology, which represents a substantial expansion of the company’s total addressable market. This cutting-edge device has been approved for the treatment of functional abdominal pain (FAP) and related nausea symptoms in patients aged 8 years and older, marking a landmark achievement as the first FDA clearance for treatment of functional dyspepsia in adults.

The FDA’s decision is based on comprehensive clinical evidence validating the safety and efficacy of PENFS in both pediatric and young adult demographics. This clearance not only enhances the therapeutic landscape for Neuraxis’s innovations but also positions the company favorably for significant revenue growth within the gastrointestinal sector, directly addressing a pressing need among patients experiencing challenging symptoms.

Brian Carrico, President and CEO of Neuraxis, emphasized the significance of this approval, stating, “This represents a crucial milestone for Neuraxis, enhancing our commitment to provide effective therapies for those suffering from functional dyspepsia.” Additionally, Dr. Adrian Miranda, Chief Medical Officer, highlighted the transformative potential of this treatment option, pointing out its capacity to significantly enhance the quality of life for patients facing limited therapeutic alternatives.

As Neuraxis continues to advance neuromodulation therapies and expand its clinical trials to address additional conditions, it is increasingly poised to drive the adoption of innovative treatments and improve outcomes for patients grappling with chronic health challenges.

Related news for (NRXS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.